ArticleISRN oncology2012
Carbonic anhydrase I as a new plasma biomarker for prostate cancer.
Article in ISRN oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Proteome profiling reveals early diagnostic biomarker candidates for colorectal cancer.BMC cancer · 2026Article
- Inhibitory Effect of Human Anti-CA I Autoantibodies and Development of Monoclonal Antibody mAb 2B8 Targeting Carbonic Anhydrase I.Mediators of inflammation · 2024Article
- Spontaneous regression of tumours. Possible cross reactivity of autoantibodies against carbonic anhydrase I.Journal of cellular and molecular medicine · 2023Article
- Construction of 2DE Patterns of Plasma Proteins: Aspect of Potential Tumor Markers.International journal of molecular sciences · 2022Article
- Impact of hemolysis on multi-OMIC pancreatic biomarker discovery to derisk biomarker development in precision medicine studies.Scientific reports · 2022Article
- The Role and Underlying Mechanism of Exosomal CA1 in Chemotherapy Resistance in Diffuse Large B Cell Lymphoma.Molecular therapy. Nucleic acids · 2020Article
- Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer.Cancers · 2020Review
- Carbonic anhydrases as disease markers.Expert opinion on therapeutic patents · 2019Review
- Silencing of carbonic anhydrase I enhances the malignant potential of exosomes secreted by prostatic tumour cells.Journal of cellular and molecular medicine · 2019Article
- Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning.EBioMedicine · 2019Article
- Carbonic Anhydrases: Role in pH Control and Cancer.Metabolites · 2018Review
- Silencing of CA1 mRNA in tumour cells does not change the gene expression of the extracellular matrix proteins.Journal of cellular and molecular medicine · 2018Article
- Synthesis and bioactivity of several new hetaryl sulfonamides.Journal of enzyme inhibition and medicinal chemistry · 2017Article
- PTPRQ as a potential biomarker for idiopathic normal pressure hydrocephalus.Molecular medicine reports · 2017Article
- Sera of patients with spontaneous tumour regression and elevated anti-CA I autoantibodies change the gene expression of ECM proteins.Journal of cellular and molecular medicine · 2017Article
- Differentially expressed and activated proteins associated with non small cell lung cancer tissues.Respiratory research · 2015Article
- A Magnetic Bead-Based Sensor for the Quantification of Multiple Prostate Cancer Biomarkers.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum prostate-specific antigen (PSA) levels ranging from 4 to 10 ng/mL is considered a diagnostic gray zone for detecting prostate cancer because biopsies reveal no evidence of cancer in 75% of these subjects. Our goal was to discover a new highly specific biomarker for prostate cancer by analyzing plasma proteins using a proteomic technique. Enriched plasma proteins from 25 prostate cancer patients and 15 healthy controls were analyzed using a label-free quantitative shotgun proteomics platform called 2DICAL (2-dimensional image converted analysis of liquid chromatography and mass spectrometry) and candidate biomarkers were searched. Among the 40,678 identified mass spectrum (MS) peaks, 117 peaks significantly differed between prostate cancer patients and healthy controls. Ten peaks matched carbonic anhydrase I (CAI) by tandem MS. Independent immunological assays revealed that plasma CAI levels in 54 prostate cancer patients were significantly higher than those in 60 healthy controls (P = 0.022, Mann-Whitney U test). In the PSA gray-zone group, the discrimination rate of prostate cancer patients increased by considering plasma CAI levels. CAI can potentially serve as a valuable plasma biomarker and the combination of PSA and CAI may have great advantages for diagnosing prostate cancer in patients with gray-zone PSA level.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.